News Release

Illumina Announces Its First Full Coverage DNA Sequencing of a Named
Family

SAN DIEGO, Apr 16, 2010 (BUSINESS WIRE) --Illumina, Inc. (NASDAQ:ILMN) today announced that it has sequenced the
DNA of John, Judy, Anne and Paul West, the first publicly named family
to have their DNA sequenced to full coverage by the company. The service
was completed in Illumina's CLIA certified and CAP accredited laboratory
utilizing Illumina's Genome Analyzer technology and following the
established process shown at http://www.everygenome.com/.

"We are excited to work with the Wests to produce our first named family
DNA sequence," said Jay Flatley, president and CEO of Illumina. "John
West has been a leader in this field for almost 30 years, including his
tenure as CEO of Solexa prior to that company's acquisition by Illumina
in 2007. We're delighted to welcome him back as a customer, and
appreciate the vote of confidence in selecting Illumina to provide his
family's sequencing. This represents an important step forward for
genetic research as sequencing moves from single individuals to full
families. More comprehensive information about a family's genetic makeup
will lead to greater understanding of the human genome and help
physicians make better healthcare decisions for their patients in the
future."

"Sequencing individuals provides fantastic visibility into our genetic
makeup," said Mr. West, who is currently CEO of Novocell, Inc., a stem
cell engineering company. "By sequencing a family of at least four we
can go a step further to interpret compound heterozygote variations in
genes - those cases where multiple variations in a single gene, but on
opposing chromosome copies, combine as a virtual homozygote. I expect
that these are much more prevalent, and the source of much more
phenotypic variability, than previously understood. Working with medical
geneticists, we look forward to exploring this new visibility into
factors influencing our future health."

When approached to consider the proposed sequencing of the Wests'
underage children, Anne and Paul, the Illumina team assessed the West
family's de-identified application to be sequenced and, following the
order from their prescribing physician and external medical advice,
supported the project. Mr. Flatley said, "While we see substantial
potential medical benefit from sequencing, and particularly of families,
we feel it is important to be thorough and diligent in pursuing
ethically well guided protocols." The Wests have elected to submit only
one parental genome data set - and none of the children's data - to the
NCBI database. Their children will have the opportunity to decide if
they wish to submit their genome data set to the NCBI once they turn 21.

The Wests feel strongly that it is important to have forward visibility
of potential health risks. If these reveal predisposition to currently
incurable diseases, the Wests feel they can take action, even as
non-scientists, by participating in clinical trials, raising money for
research and political activism. Earlier genetic testing, based on
Illumina genotyping arrays, led the Wests to seek non-genetic
confirmatory testing, with a successful outcome. Family sequencing is
their next step in this proactive approach.

Illumina (http://www.illumina.com)
is the leading developer, manufacturer, and marketer of integrated
systems for the analysis of genetic variation and biological function.
Using our proprietary technologies, we provide a comprehensive line of
products and services that currently serve the sequencing, genotyping,
and gene expression markets, and we expect to enter the market for
molecular diagnostics. Our customers include leading genomic research
centers, pharmaceutical companies, academic institutions, clinical
research organizations, and biotechnology companies. Our tools provide
researchers around the world with the performance, throughput, cost
effectiveness, and flexibility necessary to perform the billions of
genetic tests needed to extract valuable medical information from
advances in genomics and proteomics. We believe this information will
enable researchers to correlate genetic variation and biological
function, which will enhance drug discovery and clinical research, allow
diseases to be detected earlier, and permit better choices of drugs for
individual patients.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.